Výsledky vyhledávání - "Ezra Margona"

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)

Autor: Ezra Margona, James J. Harding, Mikaela Bradley, Leonard B. Saltz, Marinela Capanu, Erica Salehi, Kenneth H. Yu, Andrea Cercek, Ghassan K. Abou-Alfa, Trevor Witter, Maeve A. Lowery, Eileen M. O'Reilly, Ellen Hollywood, Scott R. Gerst

Publikováno v: Journal of Clinical Oncology. 35:290-290

290 Background: Activating mutations in the RAS/RAF/MEK/ERK signaling pathway are commonly found in ABC. MEK162 is an oral, selective small molecule inhibitor of MEK1/2; single agent activity of MEK162 in ABC has previously been observed. Preclinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12102e2ddcee8ae3231b7a5f6ee10e56
https://doi.org/10.1200/jco.2017.35.4_suppl.290

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání